Coronavirus Vaccine Updates: Bharat Biotech's Covaxin will be 60% effective; company aiming to launch vaccine in Q2 of 2021
New Delhi | Jagran News Desk: The World Health Organisation (WHO) has announced the second wave of the novel coronavirus pandemic which catalyses the countries across the globe to speed up working on their vaccine candidate against the deadly virus. Currently, around 44 vaccine candidates are in clinical trials and five vaccine candidates are in advanced stages, 4 undergoing fourth and third phase testing and others are in the first phase of the development. The top vaccine candidates for ragging COVID-19 include Pfizer, CoronaVac AstraZeneca, SputnikV, Johnson and Johnson.
Amidst the trials and peer-previews, the American pharmaceutical company Pfizer Inc and its German partner BioNTech have asked the US Food and Drug Administration (FDA) for emergency use authorisation.
Talking about the current status of Coronavirus, the world witnessed 55.6 million cases, out of which, 35.8 million have recovered. Whereas, around 1.5 million people have lost their lives due to this deadly virus. India has the second-highest cases of coronavirus in the world after the United States. Around 9.1 million cases and 133 thousand deaths have recorded so far.
Here are the Coronavirus Vaccine updates:
4:00 pm| Co-director of the Global Health Centre at the Graduate Institute of International and Development Studies in Geneva had said that lower- and middle-income nations are dependent on Oxford's Astra. The University of Oxford accounts for more than 40% of the supplies for these countries.
3:30 pm| After a review meeting on India's COVID-19 vaccination strategy, Prime Minister Modi on Friday tweeted, "Reviewed various issues like prioritisation of population groups, reaching out to HCWs (health care workers), cold-chain Infrastructure augmentation, adding vaccinators and tech platform for vaccine roll-out."
3:00 pm| Pfizer Inc, a coronavirus vaccine candidate, which has successfully received the emergency use authorization (EUA) on Friday from US health regulators. Now, other candidates like, Astrazeneca, Covaxin, Sputnik V and others are looking for the same.
2:45 pm| As per a report published in Money Control, Moderna--the US-based pharmaceutical company--is likely to submit an Emergency Use Authorization (EUA) application with the USFDA soon. The COVID-19 vaccine is said to be 94.5 per cent effective.
2:30 pm| Bharat Biotech's indigenous vaccine Covaxin had started its phase three trials earlier this month. According to a report published by India Today, President of Quality Operations at Bharat Biotech Sai D Prasad said on Sunday that its coronavirus vaccine candidate will be 60 per cent effective.
2:15 pm| As per the World Health Organisation (WHO), India's Central Drugs Standard Control Organisation (CDSCO) and United States Food and Drug Administration (USFDA), the drug can be approved if it was at least 50 per cent effective.
2:00 pm| According to a report published in Reuters, the United States drug regulators gave emergency approval to a Covid-19 antibody therapy on Saturday. The US is the most affected nation by the coronavirus pandemic across the globe with the coronavirus cases surpassing 12 million.
1:45 pm| Earlier this week, Serum Institute of India's chief executive Officer Adar Poonawalla had said that Covishield will likely to seek India’s top drug regulator's emergency approval next month for limited use in India. The vaccine will be used on frontline workers and the elderly.
View this post on Instagram
1:30 pm| This clip titled 'The Road to a Vaccine', Jassen Global Head of R&D, Dr. Mathai Mammen, discusses how the company’s new global clinical trial phase will work, how safety is a top priority, and why the company has chosen to vaccinate up to 60,000 people in Phase 3.
1:15 pm| According to Entrepreneur en Espanol-- a Spanish edition-- Joaquín Duato, vice president of the Executive Committee of Johnson & Johnson has said that its coronavirus vaccine will be released in the second half of 2021.
1:00 pm| According to a report published in Reuters, Russia’s President Vladimir Putin on Saturday told G20 leaders that Russia was ready to provide its Sputnik V coronavirus vaccine to other countries. Also, the country is working on its second and third vaccine candidate.
12:45 pm| Human trials for Russia's coronavirus vaccine candidate Sputnik-V is likely to begin in India this week. “All necessary requirements are in place, especially the mandatory regulatory approvals, for human trials to start. It is likely to commence this week, NDTV quoted a government official as saying
12:30 pm| According to a report published in Business Standards, Chief Executive Stephane Bancel told German weekly 'Welt am Sonntag' (WamS) that Moderna (Massachusetts-based biotechnology company) will charge governments between $25 and $37 per dose of its Covid-19 vaccine candidate. However, the amount may vary depending on the demand for the vaccine.
12:15 pm| Earlier this week, Chinese researchers claim that China's CoronaVac vaccine candidate is capable of inducing a quick antibody response within a 14-day interval of immunisation. However, the antibodies formed by the vaccine are less than the antibodies formed in the naturally recovered patient.
12:00 pm| According to a report published in Business Today, Dr Vinod Paul, member Niti Aayog and chairman of the National Expert Group on Vaccine Administration for COVID-19, has said, "We expect emergency authorisation for Oxford-Astrazeneca vaccine to be sought in the UK. If so, it will give an opportunity for India regulator also (to consider such an option)."
11:45 am| The third phase human trial of Covaxin had begun at the Institute of Medical Sciences and SUM Hospital, Odisha. Also, Bharat Biotech plans to enroll 1,000-2,000 volunteers each in metros like Mumbai, Hyderabad, Delhi and Kolkata.
11: 20 am| Earlier this week, Serum Institute of India's chief executive Officer Adar Poonawalla had said that about 300-400 dozes of the vaccine will be available for the first quarter of 2021.
11:00 am| According to a report published in BBC, different vaccine candidates have their different vaccine type, doses, effects and storage guidelines.
10:40 am| Pfizer, which has completed phase three trials has RNA type combination and it has two doses which are 90 per cent effective. Pfizer requires -70 degree Celcius to remain active. BioNTech has similar properties like Pfizer.
10:20 am| UK's Moderna has an RNA type combination with 95 per cent successful result. However, it has not yet peer-reviewed. This vaccine can be stored up to 6 months at -20C.
10:00 am| Oxford's Uni-AstraZeneca is a viral vector combination. After phase two results and peer-review, Oxford Uni-AstraZeneca has a strong immune response. It can be stored at regular fridge temperature.
9:30 am| Gamaleya (Sputnik V) is also a viral vector combination (genetically modified virus). According to the preliminary phase three results, the vaccine candidate is 92 per cent effective and can be stored at the fridge temperature.
Bharat Biotech's indigenous vaccine Covaxin had started its phase three trials earlier this month. According to a report published by India Today, President of Quality Operations at Bharat Biotech Sai D Prasad said on Sunday that its coronavirus vaccine cantidate will be 60 per cent effective. As per the World Health Organisation (WHO), India's Central Drugs Standard Control Organisation (CDSCO) and United States Food and Drug Administration (USFDA), the drug can be approved if it was at least 50 per cent effective.
Posted By: Srishti Goel